Cambridge Investment Research Advisors, Inc. Beam Therapeutics Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 10,578 shares of BEAM stock, worth $256,304. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,578
Previous 10,435
1.37%
Holding current value
$256,304
Previous $256,000
2.34%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding BEAM
# of Institutions
253Shares Held
78.6MCall Options Held
304KPut Options Held
142K-
Farallon Capital Management LLC San Francisco, CA8.24MShares$200 Million1.09% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$185 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.62MShares$185 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.07MShares$171 Million1.53% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.54MShares$110 Million70.85% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.7B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...